VANGUARD CPV
देश: आयरलैंड
भाषा: अंग्रेज़ी
स्रोत: HPRA (Health Products Regulatory Authority)
उत्पाद विशेषताएं
(SPC)
26-05-2024
इस उत्पाद के लिए कुछ दस्तावेज़ वर्तमान में उपलब्ध नहीं हैं, आप हमारी ग्राहक सेवा को अनुरोध भेज सकते हैं और जैसे ही हम उन्हें प्राप्त करने में सक्षम होंगे, हम आपको सूचित करेंगे।
अनुरोध भेजा।
अनुरोध भेजा।
सक्रिय संघटक:
CANINE PARVOVIRUS, STRAIN NL-35-D, LIVE ATTENUATED
थमां उपलब्ध:
Pfizer Healthcare Ireland
ए.टी.सी कोड:
QI07AD01
फार्मास्यूटिकल फॉर्म:
Solution for Injection
चिकित्सीय समूह:
Immunological - Live Vaccine
चिकित्सीय क्षेत्र:
Canine
प्राधिकरण की तारीख:
2004-05-28
उत्पाद विशेषताएं
IRISH MEDICINES BOARD ACT 1995, AS AMENDED
EUROPEAN COMMUNITIES (ANIMAL REMEDIES) (NO. 2) REGULATIONS 2007
VPA: 10019/072/001
Case No: 7007027
The Irish Medicines Board in exercise of the powers conferred on it by Animal Remedies (No. 2) Regulations (S.I. No. 786 of 2007) hereby
grants to:
PFIZER HEALTHCARE IRELAND
TRADING AS: PFIZER ANIMAL HEALTH, RINGASKIDDY, CO. CORK, IRELAND
an authorisation, subject to the provisions of the said Regulations and the general conditions of the attached authorisation, in respect of the
Veterinary Medicinal Product:
VANGUARD CPV
The particulars of which are set out in the attached Schedule. The authorisation is also subject to any special conditions as may be specified in
the Schedule.
The authorisation,unless revoked, shall continue in force from 30/08/2010.
Signed on behalf of the Irish Medicines Board
________________
A person authorised in that behalf by the said Board.
(NOTE: This authorisation replaces any previous authorisation in respect of this product which is now null and void.)
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 31/08/2010_
_CRN 7007027_
_page number: 1_
PART II
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Vanguard CPV
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Quantity per 1 ml dose
ACTIVE SUBSTANCE(S):
Live attenuated canine Parvovirus, strain NL-35-D, low passage, minimum : 10
7.0
CCID
50
*
*Cell culture infectious dose-50
For a full list of excipients see section 6.1.
3 PHARMACEUTICAL FORM
Solution for injection.
The liquid is slightly turbid, reddish in colour.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs from 5 weeks of age.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Active immunisation of
पूरा दस्तावेज़ पढ़ें
